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Abstract: Context. POEMS syndrome is a rare multisystem disorder characterised by
polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative
disorder and skin changes among other features.
Objective. To describe the prevalence and course of the endocrine dysfunction in the
context of POEMS.
Design. Cohort study with systematic review of the endocrinopathy in POEMS.
Setting. 75 patients with POEMS were evaluated by the multidisciplinary team at our
tertiary specialist centre.
Patients.  Endocrine data was available for 59 patients who attended the clinic from
06/1999 to 05/2018.
Interventions. All patients had regular endocrine screening including testing for
diabetes, pituitary and thyroid dysfunction and assessment of bone metabolism.
Main Outcome Measure. Prevalence and survival time to develop endocrinopathy in
POEMS.
Results. Thirty-four (63%) patients presented with an endocrinopathy at point of
POEMS diagnosis and 54 (92%) had at least one endocrine abnormality at follow-up.
The median follow-up was 4.4[1.5, 7.9] years. The most common endocrine
abnormality was hypogonadism in 68%, followed by hyperprolactinaemia (56%),
hypothyroidism (54%), abnormal glucose metabolism (24%), adrenal insufficiency
(17%) and high IGF-1 levels (15%). Spontaneous resolution of endocrine abnormalities
at the end of follow-up was observed: 14% in hypogonadism, 42% in
hyperprolactinaemia, 34% in hypothyroidism and 38% in high IGF-1 levels.
Conclusions. Endocrinopathy was found in 63% of patients at diagnosis and in 92% of
patients during follow-up in our cohort, therefore patients with POEMS should be
systematically assessed for endocrinopathy. The most common deficiencies were
hypogonadism and hypothyroidism, however normalisation of the endocrinopathy can
occur so on-going treatment should remain under review.
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Reviewer 1: Major Comments 
 
1. The study was retrospective and from 2013 on prospective. The study was performed in a 
quaternary referral clinic. Therefore the study was susceptible to bias in data selection, 
analysis and conclusions. 
 
We thank the referee for his/her comment. Due to the extreme rarity of POEMS syndrome, 
our quaternary referral patient dataset is likely to be the only one in the UK with a significant 
number of patients that allows a study of this nature. Also, our centre is unique as we have a 
multidisciplinary approach including endocrine specialist support. Nevertheless, we agree 
with the referee that our manuscript has inherent limitations due to its observational nature. 
Thus, we have emphasised this in the limitation section (page 14, lines 301-303: “part of the 
data was collected retrospectively, therefore it is susceptible to a selection bias. Due to the 
observation nature of the study, causal relationships cannot be stablished”). 
 
2. It is not mentioned that appropriate informed consent was obtained for the prospective 
part of the study. 
 
We apologise for the lack of clarity and have added the following information into the 
material and methods section: “All the cohort have signed informed consent for POEMS data 
collection” (page 6, lines 94-95). 
 
3. Endocrine data were only available from 59 out of 75 patients. No standardized protocol 
was used to study the incidence and prevalence of the endocrinopathies. Nevertheless, the 
authors recommended that patients should be systematically assessed for endocrinopathy at 
each visit. 
 
The referee raises an interesting point. We do have a systematic and standardised protocol 
at each visit for the endocrine assessment of patients with POEMS syndrome, which includes 
an order set of blood test and endocrine assessment by an SpR or above. We have clarified 
this point in the methods section (page 6, line 96-97).  
In our experience, endocrinopathy can easily be misdiagnosed without a proper screening 
due to other symptoms (i.e. polyneuropathy) masking the endocrine disease. Of note, our 
results are in agreement with other studies regarding the high prevalence of endocrine 
abnormalities in context of POEMS; therefore, it seems reasonable to assess these patients 
systematically. Nevertheless, we have made a minor change in our conclusion (page 14, line 
313).  
 
4. The included patients are phenotypically not well described. No information is presented 
about prevalence of polyneuropathy, organomegaly, monoclonal gammopathy and skin 
changes in the study population. 
 
We agree with the referee’s comment that this is an important point. All patients had 
monoclonal gammopathy at diagnosis and all patients except one had polyneuropathy. The 
one without neuropathy had Castleman variant POEMS. Thirty-five patients (59.3%) had 
Point-by-Point Rebuttal
organomegaly and 41 (69.5%) skin changes. We have added this information in the 
manuscript (page 8, line 144-146). Nevertheless, the complete phenotype of the patient 
cohort, excluding the endocrine description, is the subject of a publication of the natural 
history of POEMS syndrome, to be published by or group shortly.   
 
5. No information is reported about presenting symptoms of POEMS. How often was this an 
endocrinopathy/gyneacomastia? 
 
This is a very interesting comment. Unfortunately, since endocrinopathy is minor criteria and 
since thyroid abnormalities are not sufficient to meet the minor criteria, we do not have 
reliable information about how many patients had endocrinopathy as a presenting symptom 
or gynecomastia. Even so, we know that 63% of patients had clinical evidence of an 
endocrinopathy at the point of POEMS diagnosis, but we cannot establish the order of 
appearance. This data is already in the manuscript (page 8, lines 146-147).  
 
6. The prognosis of POEMS syndrome is dependent on the extent of the underlying plasma cell 
disorder and its response to treatment. However, the authors did not present any information 
about underlying plasma disorder, treatment regimens (how many participants were treated 
by melphalan/corticosteroids/radiotherapy) and responses to treatment. 
 
We acknowledge that this is very important information, however this is not the scope of our 
manuscript, which aims to focus about the endocrine abnormalities. As we mentioned above, 
the complete phenotype including treatment and prognosis of the patient cohort is due to be 
published by our group.   
 
7. Only nine of the thirty-three patients with hyperprolactinaemia underwent a pituitary or 
head MRI. The authors suggested that an indication to perform a MRI was only present if the 
hyperprolactinaemia was symptomatic or if prolactin was raised more than 3 times above the 
upper limit of reference. This is an arbitrary decision rule which is not well supported by 
arguments. 
 
The referee raises an interesting point and we agree that this is an arbitrary criterion. In our 
study, the request of an MRI was dependent on the judgement of the clinician. 
According to endocrine guidelines, MRI should be performed after detail clinical review, after 
excluding secondary causes of hyperprolactinaemia (i.e drugs) and in case of persistent 
hyperprolactinaemia; however, the significance and cause of hyperprolactinaemia is 
unknown in POEMS syndrome. Since there is not consensus for an existent cut-off for 
prolactin levels to request an MRI, we have deleted this cut-off criteria from our manuscript 
(page 12, line 252).  
 
 
8. Page 11, lines 239-241; Since there were no differences between primary and central 
hypogonadism, the authors suggested that hyperprolactinemia was not the cause of 
hypogonadism. This is pure speculation. Did they measure levels of gonadotrophines in all 
participants with hypogonadism? What was their definition of primary and central 
hypogonadism? 
 
We agree with the referee’s comment and we have rephrased ”69.2% patients with 
hyperprolactinaemia had hypogonadism, but there were no differences between primary 
and central hypogonadism; as hyperprolactinaemia was mild, this suggests the 
hyperprolactinaemia may not be the cause of the hypogonadism” (page 12, lines 246-248). 
LH/FSH was measured in all subjects to differentiate between primary and secondary 
hypogonadism. We have added the definition of primary and secondary hypogonadism 
(page 7, lines 116-119). 
 
9. IGF-I was increased while there was no evidence of increased activity of GH. How many of 
the participants were using corticosteroids with persistent high IGF-I?. 
 
The referee raises an interesting point. Out of five patients with persistent high IGF-1, only 
one was on hydrocortisone 10/5/5 mg due to adrenal insufficiency. The rest of them were 
not on treatment with any type of corticosteroids. We have added this information in the 






Reviewer 2:  
The study conducted by Caimari et al. reports the prevalence and course of endocrinopathy in 
POEMS. Although several limitations (which are addressed by the authors in the discussion) 
exist due in part to the retrospective nature of the work, the paper reports original data, with a 
significant number of patients, in a rare pathological condition. Text and figures are concise 
and well presented, an upmost need, to make this manuscript one of the reference on the 
topic of POEMS 
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Context. POEMS syndrome is a rare multisystem disorder characterised by polyneuropathy, 30 
organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder and skin changes 31 
among other features.  32 
Objective. To describe the prevalence and course of the endocrine dysfunction in the context of 33 
POEMS. 34 
Design. Cohort study with systematic review of the endocrinopathy in POEMS. 35 
Setting. 75 patients with POEMS were evaluated by the multidisciplinary team at our tertiary 36 
specialist centre. 37 
Patients.  Endocrine data was available for 59 patients who attended the clinic from 06/1999 to 38 
05/2018.  39 
Interventions. All patients had regular endocrine screening including testing for diabetes, 40 
pituitary and thyroid dysfunction and assessment of bone metabolism. 41 
Main Outcome Measure. Prevalence and survival time to develop endocrinopathy in POEMS. 42 
Results. Thirty-four (63%) patients presented with an endocrinopathy at point of POEMS 43 
diagnosis and 54 (92%) had at least one endocrine abnormality at follow-up. The median 44 
follow-up was 4.4[1.5, 7.9] years. The most common endocrine abnormality was hypogonadism 45 
in 68%, followed by hyperprolactinaemia (56%), hypothyroidism (54%), abnormal glucose 46 
metabolism (24%), adrenal insufficiency (17%) and high IGF-1 levels (15%). Spontaneous 47 
resolution of endocrine abnormalities at the end of follow-up was observed: 14% in 48 
hypogonadism, 42% in hyperprolactinaemia, 34% in hypothyroidism and 38% in high IGF-1 49 
levels.  50 
Conclusions. Endocrinopathy was found in 63% of patients at diagnosis and in 92% of patients 51 
during follow-up in our cohort, therefore patients with POEMS should be systematically 52 
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assessed for endocrinopathy. The most common deficiencies were hypogonadism and 53 
hypothyroidism, however normalisation of the endocrinopathy can occur so on-going treatment 54 
should remain under review. 55 
 56 




Description of the endocrine dysfunction in a cohort with POEMS syndrome, evaluated by a 59 
multidisciplinary team. All patients had regular screening of diabetes, pituitary, thyroid and 60 




POEMS syndrome is a paraneoplastic disorder secondary to a plasma cell dyscrasia (1). The 63 
first case of POEMS syndrome was reported in 1934, and the POEMS acronym was used in 64 
1980 for the first time (1). This rare multisystem disorder is characterised by Polyneuropathy, 65 
Organomegaly, Endocrinopathy, Monoclonal plasma-proliferative disorder and Skin changes 66 
among other features (2,3).  POEMS syndrome is also referred to as Crow-Fukase syndrome or 67 
Takatsuki syndrome (4).  68 
The aetiology of POEMS syndrome is unknown, although an increase in plasma or serum levels 69 
of vascular endothelial growth factor (VEGF) is one of the biochemical typical features (4). The 70 
diagnosis is often delayed due to the rarity of the syndrome and  patients are frequently 71 
misdiagnosed with other neurological disorders, most commonly with chronic inflammatory 72 
demyelinating polyradiculoneuropathy (5).   73 
POEMS syndrome involves multiple organs, and therefore a multidisciplinary approach is 74 
usually necessary to treat this group of patients, including a thorough endocrine assessment.  75 
Multiple endocrinopathies have been described in POEMS, however the pathogenesis 76 
underlying the endocrine abnormalities in POEMS syndrome is unknown. The endocrine 77 
dysfunction reported so far is diverse and includes both primary and secondary insufficiencies,  78 
such as hypothyroidism, adrenal insufficiency, hypoparathyroidism and hypogonadism (6) as 79 
well as excess of hormones with hyperprolactinaemia and hyperparathyroidism (7,8). Pituitary 80 
tumours have been described (9), but this could be an incidental finding as the prevalence of 81 
these tumours is approximately 20% in the general population (10).  82 
There is a significant risk of morbidity from unrecognised endocrinopathy in these patients, 83 
especially if there is a lack of a multidisciplinary approach. Little is known about the course and 84 
severity of the endocrine dysfunction in POEMS. Here we describe the endocrinopathy at 85 
diagnosis and during follow-up in the largest reported European cohort of patients with POEMS 86 
syndrome seen at a single specialist centre. 87 
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MATERIAL AND METHODS 88 
Seventy-five patients were identified fulfilling the internationally accepted POEMS diagnostic 89 
criteria (see Table 1), attending a quaternary referral clinic at University College London 90 
Hospital (UCLH), from 1999 to May 2018 referred from other centres in the UK and Ireland. 91 
Endocrine data was available from 59 patients who attended the joint haematological / 92 
neurological /endocrine clinic. Endocrine data was collected initially retrospectively from 93 
medical notes and prospectively from 2013. All the cohort have signed informed consent for 94 
POEMS data collection. All patients had at least six monthly regular endocrine screening 95 
including diabetes, pituitary, thyroid and bone metabolism, including clinical assessment and an 96 
order set of blood test according to our protocol. Those patients with only endocrine screening 97 
at diagnosis, without endocrine follow-up, or followed in another hospital were excluded from 98 
this study. Other non-endocrine features and treatment of this cohort of POEMS syndrome 99 
patients has been described elsewhere (Keddie et al, manuscript in progress).  100 
Definition of variables 101 
POEMS syndrome was diagnosed when patient fulfilled the diagnostic criteria (5) (Table 1). 102 
The date of diagnosis was defined as the date of confirmation of POEMS syndrome. Last 103 
follow-up was defined as the last hospital appointment in our institution.  104 
We defined endocrine abnormality at diagnosis if the patient presented before or at the moment 105 
of POEMS syndrome diagnosis with one or more of the following comorbidities: diabetes 106 
mellitus (DM), thyroid disease, hypogonadism, adrenal insufficiency, hyperprolactinaemia, 107 
hypo/hyperparathyroidism.  We defined endocrinopathy at follow-up if the patient newly 108 
presented with any of those abnormalities during follow-up, in addition to abnormal IGF-1 109 
levels. 110 
New primary hypothyroidism was defined as two separate thyroid stimulating hormone (TSH) 111 
levels above the reference range (0.27-4.20 mIU/L). DM and pre-diabetes were diagnosed 112 
according to the ADA criteria (11). Hyperprolactinaemia was defined when at least two 113 
prolactin levels were above the reference range (324 pmol/L for men and 496 pmol/L for 114 
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women). Hypogonadism in men was defined when testosterone level at 9 am was below the 115 
reference range on at least two occasions (7.6 mmol/L) with elevated LH/FSH in primary 116 
hypogonadism and low or normal LH/FSH in secondary hypogonadism. Hypogonadism in 117 
women was defined when amenorrhoea was present with low oestrogen, and abnormally low 118 
LH/FSH levels in secondary hypogonadism or high LH/FSH levels in primary hypogonadism. 119 
Women with amenorrhoea, high LH/FSH levels and above 45 years old were considered to be 120 
in the menopause and were thus not considered as having pathological hypogonadism.  Adrenal 121 
insufficiency was defined as clinical symptoms of hypoadrenalism and basal cortisol below 100 122 
nmol/L in the absence of exogenous corticosteroid administration or abnormal short synacthen 123 
test. High IGF-1 levels were considered when IGF-1 was elevated above the age adjusted 124 
reference range at least on two occasions.  125 
Statistical analysis 126 
The Shapiro-Wilks test was used to assess normal distribution for continuous variables. 127 
Normally distributed variables were expressed as mean and standard deviation (SD) and were 128 
analyzed with the Student t-test. Median and interquartile range (IQR) were used to describe 129 
non-normally distributed variables. These variables were analyzed with the Mann-Whitney U-130 
test. Qualitative variables were expressed as percentage and analyzed with the chi-square test to 131 
compare two or more groups. Kaplan Meier (KM) curves were calculated for each endocrine 132 
dysfunction to estimate their survival time. Patients with endocrinopathy at diagnosis were 133 
excluded for KM calculation. P<0.05 was taken as significant. 134 
 135 
RESULTS 136 
Baseline characteristics 137 
Fifty-nine patients had endocrine follow-up. All patients fulfilled the minimum criteria for 138 
POEMS diagnosis (Table 1). Thirty-nine patients were male (66.1%) and the median age of 139 
diagnosis was 52.5 [38.6, 63.3] years with no differences between gender (53.3 [40.6,73.4] 140 
years for men vs 47.8 [37.4,72.8] years for women, p=0.147). Five patients (9.6%) were active 141 
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smokers at diagnosis and 23.1% were ex-smokers. The median follow-up was 4.4 [1.5, 7.9] 142 
years.   143 
All patients had monoclonal gammopathy at diagnosis and all patients except one had 144 
polyneuropathy. The one without neuropathy had Castleman variant POEMS. Thirty-five 145 
patients (59.3%) had organomegaly and 41 (69.5%) skin changes. Thirty-four (63%) patients 146 
had clinical evidence of an endocrinopathy at the point of POEMS diagnosis. Endocrine 147 
abnormalities at presentation are described in Table 2. Two patients presented with an empty 148 
sella, one with panhypopituitarism with ACTH, TSH, FSH/LH deficiency and 149 
hyperprolactinemia, and the other with normal pituitary function but with primary 150 
hypothyroidism and type 2 DM.  151 
Endocrine abnormalities at follow-up  152 
Fifty-four patients (91.5%) had an endocrinopathy at some point during follow-up (25.4% with 153 
one endocrine abnormality, 23.7% with two, 28.8% with three, 8.5% with four, 3.4% with five 154 
and 1.7% with six abnormalities). None of our patients developed hypo- or hyperparathyroidism 155 
during follow-up. The next sections describe the endocrine abnormalities with their relevant 156 
treatment, ranked by their frequency (summarized in Table 3). 157 
Hypogonadism  158 
Thirty-nine (68.4%) patients presented with hypogonadism by the end of follow-up. Ten (50%) 159 
women were considered to be menopausal and therefore were not included as having 160 
pathological hypogonadism.  When studied by gender, 29 (78.4%) men and 10 (50%) of women 161 
were diagnosed with hypogonadism. From those, 16 (41%) had central hypogonadism and 23 162 
(59%) primary hypogonadism. Out of these 23 patients, 14 (60.9%) developed primary 163 
hypogonadism after receiving melphalan treatment as preconditioning for autologous stem cell 164 
transplant. The median time to develop hypogonadism after diagnosis of POEMS syndrome was 165 
3 [0.9, 5.9] years (Figure 1A). Hypogonadism spontaneously resolved in five (13.5%) patients: 166 
three with central hypogonadism and two with primary hypogonadism.  167 
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Regarding testosterone replacement, of the 29 men with hypogonadism, 14 (48.3%) did not 168 
receive any treatment. Seven (24.1%) were treated with testosterone injections and 8 (27.6%) 169 
with testosterone gel. From those treated with testosterone, six (37.5%) developed 170 
polycythaemia after testosterone replacement, in comparison to three (6.8%) that did not receive 171 
testosterone replacement (p=0.024). Five were on testosterone injections (testosterone enanthate 172 
or a combination of testosterone propionate, testosterone phenylpropionate, testosterone 173 
isocaproate and testosterone decanoate) and one on testosterone gel.  174 
Hyperprolactinaemia 175 
Thirty-three (55.9%) patients developed hyperprolactinaemia although six of these were treated 176 
with a drug with the potential to induce hyperprolactinaemia. Nine patients underwent a 177 
pituitary or head MRI. Of these, eight had a normal pituitary MRI and one presented with an 178 
empty sella. The median peak prolactin was 1.9 [1.5, 2.2] times above the upper limit of the 179 
normal range, adjusted by gender.  180 
Twenty-seven patients (69.2%) with hyperprolactinaemia had hypogonadism, without 181 
differences between central and primary hypogonadism (10 (62.5%) vs 17 (73.9%) respectively, 182 
p=0.447). 183 
The median time to develop hyperprolactinaemia during follow-up was 2.8 [0.9, 6.2] years 184 
(Figure 1B). No patient received treatment with a dopamine agonist and in 14 (42.4%) patients, 185 
the prolactin level normalised by the end of follow-up. 186 
Thyroid disease 187 
Thirty-two (54.2%) patients were diagnosed with hypothyroidism: 17 (53.1%) with clinical 188 
primary, 14 (43.8%) with subclinical primary and 1 (3.1%) with central hypothyroidism.  The 189 
median TSH value for patients with primary hypogonadism at diagnosis was 10.1±5 mIU/L 190 
(normal range 0.27-4.20 mIU/L) and all patients requiring treatment were treated with 191 
levothyroxine once a day (median dose 62.5 [37.5, 106.3] mcg). Hypothyroidism developed 192 
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after 2.64 (0.6- 4.9) years (Figure 1C). Hypothyroidism spontaneously resolved in 11 (34.4%) 193 
of these patients, three with clinical and eight with subclinical hypothyroidism. 194 
Abnormal glucose metabolism 195 
Fourteen (23.8%) patients presented with abnormal glucose metabolism, eight (13.6%) with 196 
DM (seven type 2DM and one with steroid-induced DM), and six (10.2%) with pre-diabetes.  197 
Patients with DM were treated with diet alone in one patient, four with oral hypoglycaemic 198 
drugs and three with insulin with/without oral hypoglycaemic drugs. Patients developed 199 
abnormal glucose tolerance after 3.4 [0.9, 6.1] years from the diagnosis of POEMS (Figure 1D). 200 
DM resolved in the one patient with steroid-induced diabetes.  201 
Adrenal insufficiency 202 
Ten (17%) patients presented with adrenal insufficiency at the end of follow-up. Five had 203 
primary adrenal insufficiency, one central and four with secondary cortisol deficiency due to 204 
long-term steroid treatment. None of the patients recovered from adrenal insufficiency at the 205 
end of follow-up. The median time to develop cortisol deficiency was 3.6 [1.4, 6.8] years 206 
(Figure 1E). 207 
IGF-1 208 
Eight (14.8%) patients had high IGF-1 levels on at least two different occasions. Only one 209 
patient had acromegalic features. The IGF-1 mean in these patients was 1.3±0.2 times above the 210 
upper limit of the normal range, adjusted by age. The median time to develop high IGF-1 level 211 
at follow-up was 4.3 [1.4, 8] years after diagnosis of POEMS syndrome (Figure 1D). Five 212 
patients with persistent high IGF-1 level had screening for growth hormone (GH) excess with a 213 
75g Oral Glucose Tolerance Test (OGTT). In all of them GH was adequately supressed, 214 
therefore excluding acromegaly and in only one patient was on treatment with corticosteroids 215 
(hydrocortisone 20 mg) due to adrenal insufficiency. The patient who had acromegalic features 216 
underwent a pituitary MRI, which did not demonstrate any pituitary lesion. In three (37.5%) of 217 




We have reviewed the course of endocrine dysfunction in a large group of patients with POEMS 220 
syndrome. To our knowledge, this is the largest series that systematically reviews the 221 
endocrinopathy in this rare condition. It uses endocrine data collected initially retrospectively 222 
and later prospectively during follow-up. Our cohort is characterized by diverse endocrinopathy, 223 
mostly with more than one endocrine diagnosis, and combining primary and secondary 224 
insufficiencies as well as excess of hormonal secretion. 225 
In the literature, endocrine dysfunction has been reported in 58-80% of patients (2,7). This is 226 
similar to our study, although we report a significant increase in the diagnosis during follow-up 227 
(63% at presentation vs 91.5% at follow-up), suggesting that the endocrine screening during 228 
follow-up is essential in these patients. 229 
Hypogonadism 230 
The most frequent endocrine abnormality was hypogonadism (68.4%), but hyperprolactinaemia 231 
(55.9%) and hypothyroidism (54.2%) were also common in our cohort, as previously reported 232 
(4,7,12).  Although, most patients did not have clear causes for the development of 233 
hypogonadism, some alternative or additional factors could play roles in development. Firstly, 234 
these patients were frequently ill at presentation, with a possible underlying diagnosis of 235 
hypothalamic hypogonadism, described in context of severe illness (13,14). Secondly, some of 236 
the patients developed primary hypogonadism in the context of melphalan treatment (an 237 
alkylating agent known to cause gonadal toxicity)(15), and therefore hypogonadism may not be 238 
directly related to POEMS. The combination of these three precipitating factors probably 239 
explains why hypogonadism is the most common endocrinopathy in POEMS. 240 
Hyperprolactinaemia 241 
Hyperprolactinaemia was the second most common endocrinopathy in our cohort (55.9%), and 242 
only a few patients had treatment with drugs that could induce hyperprolactinaemia. In our 243 
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cohort the frequency of hyperprolactinaemia is higher than previously reported and we 244 
hypothesise that this is the direct result of a systematic screening of these patients (7).  245 
69.2% patients with hyperprolactinaemia had hypogonadism, but there were no differences 246 
between primary and central hypogonadism; as hyperprolactinaemia was mild, this suggests the 247 
hyperprolactinaemia may not be the cause of the hypogonadism. We hypothesise that empty 248 
sella could also be an expression of endocrine abnormality in POEMS, although an incidental 249 
finding cannot be excluded as there are no other cases reported so far. Given only the mild 250 
increase in prolactin in most of our patients we suggest that a pituitary MRI should only be 251 
requested if the hyperprolactinaemia is persistent or symptomatic. 252 
Hypothyroidism  253 
Hypothyroidism was the third endocrine disease in frequency in our cohort (54.2%). Most of 254 
our patients (except one with panhypopituitarism), presented with primary hypothyroidism, and 255 
half of them had subclinical hypothyroidism. Mild elevation of TSH has been reported in other 256 
series (4,7,16). Although hypothyroidism is not considered as part of the POEMS criteria 257 
diagnosis, the prevalence of thyroid disease in POEMS is by far much higher in POEMS 258 
patients than in general population (17).  259 
Glycaemic control 260 
Patients with type 2 DM accounted for 13.6% in our cohort, however abnormal glucose 261 
metabolism reached 23.8% when pre-diabetes was also considered. The prevalence does not 262 
differ when compared with general population, although the prevalence of type 2 DM varies by 263 
region, age and ethnicity, amongst other factors (18). As type 2 DM has a high prevalence in the 264 
population, caution should be taken when considering it as part of the POEMS syndrome, 265 
especially if no other endocrine organs are affected and this is the reason why DM is not 266 
included in the POEMS diagnostic criteria. Treatment of abnormal glucose metabolism should 267 
be in line with usual recommendations. 268 
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Adrenal insufficiency  269 
Adrenal insufficiency was significant in our cohort (17%). In this group, those who had long 270 
term steroid treatment had cortisol deficiency secondary to treatment for POEMS syndrome. 271 
However, five of 59 patients (8.5%) had primary adrenal insufficiency. Different from the 272 
natural course of other endocrinopathies, adrenal insufficiency was permanent in every patient 273 
in our cohort. 274 
IGF-1 levels 275 
We report for the first time that patients with POEMS syndrome present with elevated IGF-1 276 
levels. In those with persistent high IGF-1, the OGTT, a measure of GH suppressibility, 277 
revealed a normal GH-IGF-1 axis. Of note, the increase of IGF-1 was mild in all patients. The 278 
significance of this finding is unclear and difficult to explain, especially taking into account that 279 
IGF-1 levels are usually low in the context of severe illness (19) and that IGF-1 concentrations 280 
are reduced in patients with multiple myeloma (20). Although our patients have hepatomegaly, 281 
we have not found any evidence that hepatomegaly is associated with increased IGF-1 282 
production. 283 
Interestingly, the prevalence of endocrine abnormalities increased during follow-up. The median 284 
time to develop any abnormality ranged from 2.6 to 4.3 years after POEMS presentation.  This 285 
could indicate that the endocrine organ damage continues after controlling the disease. This data 286 
was unexpected as it is well described that other features of POEMS syndrome, such as 287 
polyneuropathy, improve after treatment (21). On the other hand, we found that endocrine 288 
dysfunction can be reversible in POEMS syndrome: 42.4 % patients with hyperprolactinaemia, 289 
34.4% of patients with hypothyroidism and 37.5% in high IGF-1 levels demonstrated a transient 290 
abnormality. Of note, our patients were characterized by presenting multiple but mild 291 
endocrinopathies.  292 
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Patients received endocrine treatment according to current medical guidelines and generally 293 
wellbeing improved in these patients (author’s observation). We observed that patients with 294 
hypogonadism treated with testosterone had a high risk of polycythaemia. Polycythaemia itself 295 
is a feature commonly found in active/unremitted POEMS (2). Therefore, this cohort has a 296 
predisposition to develop polycythaemia, also a well-known side effect of testosterone 297 
treatment. In our experience, patients who received testosterone injections had higher chance of 298 
polycythaemia compared to those treated with gel, and the level of polycythaemia occasionally 299 
required cessation of testosterone treatment.  300 
This study has some limitations. Firstly, part of the data was collected retrospectively, therefore 301 
it is susceptible to a selection bias. Due to the observation nature of the study, causal 302 
relationships cannot be stablished. Secondly, due to its observational nature several questions 303 
cannot be addressed. These include the cause of the endocrine dysfunction in POEMS 304 
syndrome, how and why the endocrine disease can be reversible and why the patients present 305 
either hormonal insufficiency or hypersecretion, such as high IGF-1 levels. We will address 306 
these questions with studies of a different design. Finally, due to the high incidence in the 307 
general population of some of the endocrine diseases such as hypothyroidism or Type 2 DM, 308 
the incidental co-association of these abnormalities cannot be excluded, but is recognised. We 309 
believe that this study has highlighted several issues, which contribute to the knowledge of this 310 
rare but challenging clinical situation. 311 
In conclusion, endocrinopathy in POEMS was found in 63% of patients at diagnosis and in 312 
91.5% of patients during follow-up in our cohort. We therefore suggest the following 313 
recommendations for patients with POEMS syndrome in addition to the multidisciplinary 314 
haematological and neurological care.  315 
1) POEMS syndrome involves multiple organs, and a multidisciplinary approach should 316 
include an endocrinologist. 317 
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2) Patients should be systematically assessed for endocrinopathy at each visit and be offered 318 
endocrine treatment as indicated.  319 
3) Normalisation of the endocrinopathy occurred in a proportion of patients, so on-going 320 
treatment should remain under review.  321 
4) Adrenal insufficiency was permanent and patients will need education and advice regarding 322 
life-long steroid sick day rules. 323 
5) Patients on testosterone replacement therapy should be monitored for polycythaemia. 324 
  325 
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FIGURE LEGENDS 393 
 394 
Figure 1. Time to develop endocrinopathy in patients with POEMS syndrome. 395 
 396 
Figure 2. Endocrinopathy at follow-up and transient endocrine abnormalities. 397 
Black columns indicate the percentage of endocrinopathies at follow-up. Grey columns indicate the 398 
percentage of patients that normalise the endocrine dysfunction. 399 
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Table 1. Diagnostic criteria for POEMS syndrome (5). 
Mandatory Major Criteria 
Polyneuropathy (typically demyelinating) 
Monoclonal plasma cell proliferative disorder (almost always ʎ) 
Other Major Criteria (one required) 
Castleman disease 
Sclerotic bone lesions 
Vascular bone lesions 
VEGF elevation 
Minor criteria (one required) 
Organomegaly 





Other useful features 
Clubbing, weight loss, hyperhidrosis, pulmonary hypertension/ restrictive lung disease, 
thrombotic diathesis, diarrhoea, low vitamin B12. 
* Due to the high prevalence of diabetes mellitus and thyroid abnormalities, this diagnosis alone is not 





Table 1 Click here to access/download;Table;Table 1.docx
Table 2. Endocrine abnormalities in POEMS syndrome at diagnosis and follow-up. 







Endocrine dysfunction at diagnosis* 34 (63%) 21 (61.8%) 13 (65%) 0.812 
Thyroid disease 20 (36.4%) 12 (34.3%) 8 (40%) 0.672 
Hypogonadism 20 (36.4%) 16 (45.7) 4 (20) 0.057 
Diabetes Mellitus 4 (7.3%) 4 (11.4%) 0 0.116 
Hypoparathyroidism 0 0 0 NA 
Addison disease 3 (5.5%) 1 (2.86%) 2 (10%) 0.262 
Hyperprolactinaemia 13 (24.1%) 7 (20.6%) 6 (30%) 0.435 
Endocrine dysfunction at follow-up 54 (91.5%) 35 (89.7%) 19 (95%) 0.375 
*IGF-1 levels were not assessed at POEMS diagnosis.  
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Time of onset 





Hypogonadism 39 (68.4) 3 [0.9, 5.9] 15 (51.7) 3 (13.5) 
Hyperprolactinaemia 33 (55.9) 2.8 [0.9, 6.2] 0 14 (42.4%) 
Thyroid disease 32 (54.2%) 2.6 [0.6-4.9] 14 (43.8) 11 (34.4%) 
Abnormal glucose metabolism 14 (23.8) 3.49 [0.9-6.1] 8 (57.1) 0 
Adrenal insufficiency 10 (17) 3.6 [1.4-6.8] 10 (100) 0 
High IGF-1 8 (14.8) 4.3 [1.4-85] 0 3 (37.5) 
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